The increasing burden of the aging on the economies of the developed countries is turning the quest to increase healthy life spans from an altruistic cause into a pressing economic priority required to maintain the current standards of living and facilitate economic growth (Zhavoronkov and Litovchenko, [@B49]). There is an urgent need to develop and validate interventions with geroprotective properties to increase the productive health spans of the working population and maintaining performance and avoiding loss of function (Kennedy, [@B16]).

While no doubt exists that aging is a complex multifactorial process with no single cause or treatment (Zhavoronkov and Cantor, [@B48]; Trindade et al., [@B35]), the issue whether aging can be classified as the disease is widely debated (Rattan, [@B31]). However, many strategies for extending organismal life spans have been proposed including replacing cells (Rodgerson and Harris, [@B32]) and organs, comprehensive strategies for repairing the accumulated damage, using hormetins to activate endogenous repair processes (Gems and Partridge, [@B9]; Gaman et al., [@B8]), modulating the aging processes through specific mutations, gene therapy (Bernardes De Jesus et al., [@B2]) and small molecule drugs (Kennedy and Pennypacker, [@B17]). An animal\'s survival strongly depends on its ability to maintain homeostasis and achieved through intracellular and intercellular communication within and among different tissues (Alcedo et al., [@B1]). Many strategies for the development and validation of drugs with geroprotective properties have been proposed to help maintain the homeostasis including drugs that act on specific targets or combinations of molecular pathways (Moskalev and Shaposhnikov, [@B26], [@B27]; Zhavoronkov et al., [@B50]; Danilov et al., [@B6]) and epigenetic drugs (Vaiserman and Pasyukova, [@B37]). However, none of the proposed strategies for aging-suppressive drug development provide a roadmap for rapid screening, validation, and clinical deployment. No methods currently exist to predict the effects of currently available drugs on human longevity and health span in a timely manner. This is partly due to the absence of the clear panel of human processes involved in aging to effectively run clinical trials.

Many processes are involved in the aging of cells and organisms including telomere length (Lehmann et al., [@B22]), intracellular and extracellular aggregates, racemization of the amino acids and genetic instability. Both gene expression (Wolters and Schumacher, [@B41]) and DNA methylation profiles (Horvath et al., [@B12]; Horvath, [@B11]; Mendelsohn and Larrick, [@B24]) change during aging and may be used as biomarkers of aging. Many studies analyzing transcriptomes of biopsies in a variety of diseases indicated that age and sex of the patient had significant effects on gene expression (Chowers et al., [@B5]) and that there are noticeable changes in gene expression with age in mice (Weindruch et al., [@B39]; Park et al., [@B29]) resulting in development of mouse aging gene expression databases (Zahn et al., [@B47]) and in humans (Blalock et al., [@B3]; Welle et al., [@B40]; Park and Prolla, [@B30]; Hong et al., [@B10]; De Magalhaes et al., [@B7]).

Combination of protein-protein interaction and gene expression in both flies and humans demonstrated that aging is mainly associated with a small number of biological processes, might preferentially attack key regulatory nodes that are important for network stability (Xue et al., [@B42]).

Our prior work with gene expression and epigenetics of various solid tumors (Kuzmin et al., [@B20]; Mityaev et al., [@B25]; Zabolotneva et al., [@B45],[@B46]) using the OncoFinder system ([www.oncofinder.com](http://www.oncofinder.com)), provided clues that transcription profiles of cancer cells mapped onto the signaling pathways may be used to screen for and rate the targeted drugs that regulate pathways directly and indirectly related to aging and longevity. Instead of focusing on individual network elements, this approach involves creating the signaling pathway cloud, a collection of signaling pathways involved in aging and longevity each comprised of multiple network elements and evaluating the individual pathway activation strength. Despite significant advances in aging research, the knowledge of the aging processes is still poor, and combining all available factors involved in cellular aging, aging of the organisms, age-related diseases, stress-resistance, and stress-response along the many other factors into a comprehensive signaling pathway cloud may be more beneficial than focusing on the narrow collection of elements. The creation of the pathway cloud may allow for the annotated databases of molecules and other factors to be screened for effectiveness of individual compounds in replicating the "young" signaling activation profiles *in silico*.

Several new methods evaluating the robustness and response ability of the gene regulatory network have been developed and applied to gene expression data sets from young and old patients (Tu and Chen, [@B36]). Prior studies suggested that a combination of pathways, termed pathway cloud, instead of one element of the pathway or the whole pathway might be responsible for pathological changes in the cell (Voronkov and Krauss, [@B38]). Long-lived species like the sea urchin (*Strongylocentrotus franciscanus*) and naked mole rat (*Heterocephalus glaber*) that senesce at a slower rate than members of the same order show less transcriptome changes with age (Kim et al., [@B18]; Loram and Bodnar, [@B23]). Gene network analysis using gene expression data was effective in identifying the possible drug targets (Imoto et al., [@B13]; Savoie et al., [@B33]). *In silico* drug discovery algorithms that attempt to transform the metabolism to the healthy state have been proposed and validated (Yizhak et al., [@B44]). We theorize that in order to be effective, the geroprotector or a combination of aging-suppressive drugs must regulate the pathway cloud in a way that minimizes the difference in the net differences in pathway cloud activation or downregulation between samples of young and old patients. Small molecules and other factors that may influence gene expression may be ranked by their ability to minimize the net difference between the pathway activation profiles of young and old cells. The algorithms for calculating the ability of the potential geroprotector to minimize signaling disturbance may be parametric and account for the effects on specific targets within signaling pathways or machine learned.

Despite the differences in life span and aging phenotypes, many molecular mechanisms of aging are common in all eukaryotes. Pathway analysis revealed that there are many common age-related transcriptomic changes between different species, including yeasts, worms, flies, rodents, and human (Murphy et al., [@B28]). Hypothetically, the human orthologs of aging-related genes of model organisms are also involved in aging process. To select longevity-associated pathways for future analysis we perform the following procedure. Using (Tacutu et al., [@B34]) database we selected genes, where knockout, loss-of-function mutation, deletion or RNA interference significantly extended lifespan in several model organisms (yeasts *Schizosaccharomyces pombe* and *Saccharomyces cerevisiae*, nematode *Caenorhabditis elegans*, fruitfly *Drosophila melanogaster* and mouse *Mus musculus*) from 10 to 200%. We converted the obtained gene lists from different models to the general list of human orthologs where it is possible. 226 genes of 315 from our set were subjected to over-representation pathway analysis in (Kamburov et al., [@B14]). *P*-value and corrected by FDR *P*-value are calculated according to the hypergeometric test based on the number of physical entities present in both the predefined set of genes to each (Kanehisa et al., [@B15]) pathway and our list of aging-associated genes (Table [1](#T1){ref-type="table"}). We established limits of 2 genes of minimum overlap with input list and 0.01 *p*-value cut off threshold.

###### 

**KEGG pathways and list of aging-associated genes**.

  **KEGG pathway name**                       **Background quantity of genes in the pathway**   **Overlap with candidates list**   **%**   ***p*-Value**   **FDR**
  ------------------------------------------- ------------------------------------------------- ---------------------------------- ------- --------------- ----------
  Citrate cycle (TCA cycle)                   30                                                5                                  16.7    0.000401        0.0037
  Ribosome                                    136                                               21                                 15.7    7.52E-13        6.21E-11
  Parkinson's disease                         131                                               20                                 15.4    3.87E-12        2.02E-10
  Aldosterone-regulated sodium reabsorption   39                                                6                                  15.4    0.000165        0.00199
  Type II diabetes mellitus                   48                                                7                                  14.6    6.66E-05        0.00105
  Oxidative phosphorylation                   133                                               19                                 14.4    4.55E-11        1.78E-09
  mTOR signaling pathway                      60                                                8                                  13.3    3.89E-05        0.000764
  Huntington's disease                        183                                               24                                 13.2    7.92E-13        6.21E-11
  Progesterone-mediated oocyte maturation     86                                                11                                 12.8    2.08E-06        4.66E-05
  Insulin signaling pathway                   142                                               17                                 12.1    8.01E-09        2.10E-07
  Ovarian steroidogenesis                     51                                                6                                  11.8    0.000735        0.00525
  Long-term depression                        60                                                7                                  11.7    0.000281        0.00294
  Amyotrophic lateral sclerosis (ALS)         53                                                6                                  11.3    0.000905        0.00592
  Alzheimer's disease                         170                                               19                                 11.2    3.36E-09        1.05E-07
  Cardiac muscle contraction                  77                                                8                                  10.5    0.000214        0.0024
  Gap junction                                89                                                9                                  10.1    0.000118        0.00155
  Prostate cancer                             89                                                9                                  10.1    0.000118        0.00155
  Estrogen signaling pathway                  100                                               10                                 10.0    5.44E-05        0.00095
  Colorectal cancer                           62                                                6                                  9.7     0.00206         0.0101
  Glioma                                      65                                                6                                  9.2     0.00263         0.012
  Pancreatic cancer                           66                                                6                                  9.1     0.00284         0.0124
  GABAergic synapse                           90                                                8                                  9.0     0.000631        0.00524
  Adipocytokine signaling pathway             71                                                6                                  8.6     0.00382         0.0154
  PPAR signaling pathway                      71                                                6                                  8.5     0.0041          0.0157
  Circadian entrainment                       97                                                8                                  8.3     0.00104         0.00629
  Prolactin signaling pathway                 72                                                6                                  8.3     0.0044          0.0157
  Chronic myeloid leukemia                    73                                                6                                  8.2     0.0047          0.0164
  Cholinergic synapse                         113                                               9                                  8.0     0.000667        0.00524
  Oocyte meiosis                              112                                               9                                  8.0     0.000667        0.00524
  Serotonergic synapse                        114                                               9                                  8.0     0.000711        0.00525
  Insulin secretion                           87                                                7                                  8.0     0.00261         0.012
  Gastric acid secretion                      75                                                6                                  8.0     0.00537         0.0183
  HIF-1 signaling pathway                     106                                               8                                  7.5     0.00198         0.01
  Peroxisome                                  81                                                6                                  7.5     0.00734         0.0226
  TGF-beta signaling pathway                  80                                                6                                  7.5     0.00734         0.0226
  Cell cycle                                  124                                               9                                  7.3     0.00138         0.00803
  Dopaminergic synapse                        131                                               9                                  6.9     0.00192         0.01
  Glutamatergic synapse                       118                                               8                                  6.8     0.00366         0.0151
  Proteoglycans in cancer                     225                                               14                                 6.2     0.000348        0.00342
  RNA transport                               165                                               10                                 6.1     0.00268         0.012
  Hepatitis B                                 147                                               9                                  6.1     0.00439         0.0157
  HTLV-I infection                            267                                               14                                 5.3     0.00161         0.00869
  Chemokine signaling pathway                 192                                               10                                 5.3     0.00732         0.0226
  PI3K-Akt signaling pathway                  347                                               16                                 4.6     0.00312         0.0133

As a result we revealed overrepresented cell signaling pathways (mTOR, insulin/IGF-1, PI3K-Akt, PPAR, HIF-1, TGF-beta, chemokines, adipocytokine, prolactin, estrogen), general metabolism (TCA cycle, ribosome, oxidative phosphorylation), RNA transport, cell cycle and meiosis, gap junction, peroxisome, cyrcadian rhythm, different synapse types (dopaminergic, glutamatergic, cholinergic, serotonergic, GABAergic), gastric acid secretion as well as age-related diseases pathways (Parkinson\'s disease, type II diabetes mellitus, Huntington\'s disease, long-term depression, amyotrophic lateral sclerosis, Alzheimer\'s disease), Hepatitis B, HTLV-I infection and cancer pathways (prostate cancer, colorectal cancer, glioma, pancreatic cancer, chronic myeloid leukemia, proteoglycans in cancer). We considered obtained such a way pathways as probably associated with the human longevity. Human genes known as key activators/repressors of these pathways may be used in provided further mathematical model.

The methods that may be applied for the possible analysis of geroprotector efficiency by pathways regulation have been arisen from our research experience of cell signaling pathways. As far as we have seen before (Kiyatkin et al., [@B19]; Borisov et al., [@B4]; Kuzmina and Borisov, [@B21]), most signal transduction proteins are essentially far from saturation even at the peak concentrations of the activated form in comparison with the total protein abundances. Thus, we can consider that all activator/repressor genes/proteins have equal importance for the pathway activation/downregulation, and then arrive at the following assessment function for the overall signal pathway cloud disturbance outcome (*SPCD*) is proportional to the following estimator function, $$SPCD = \frac{\prod\limits_{i\mspace{2mu} = \mspace{2mu} 1}^{N}\left\lbrack {AGEL} \right\rbrack_{i}}{\prod\limits_{j\mspace{2mu} = \mspace{2mu} 1}^{M}\left\lbrack {RGEL} \right\rbrack_{j}}$$ Here the multiplication is done over all possible activator and repressor proteins in the pathway, and \[*AGEL*\]~*i*~ and \[*RGEL*\]~*j*~ are gene expression levels of an activator *i* and repressor *j*, respectively. To obtain an additive rather than multiplicative value, it is enough just turn from the absolute values of the expression levels to their logarithms, arriving at the *pathway activation strength* (*PAS*) value for each pathway (see Figure [1](#F1){ref-type="fig"}). To obtain the values of *Old (case)-to-Young ratio*, *YOR*~*n*~, one just has to divide the expression levels for a gene *n* in the sample taken for the senescent person by the same average value for the normalized young group. The discrete value of *ARR* (*activator*/*repressor role*) equals to the following numbers:

![**Gene expression-based approach to *in silico* screening for drugs with geroprotective properties and estimating the predicted efficacy. (A)** Using signaling pathway cloud regulation for theoretical *in silico* aging-suppressive drug identification and ranking. The proposed method for identifying and ranking of geroprotective drugs by evaluating the net effect on the many elements of signaling pathway cloud that brings the "old" metabolic state closer to the "young." **(B)** An example of how multiple pathways are activated and down-regulated during aging. **(C)** Pathway Activation Strength (PAS) is the logarithmic additive value that characterizes the up-/downregulation of signaling pathways. **(D)** Function for the overall signal pathway cloud disturbance outcome (SPCD).](fgene-05-00049-g0001){#F1}

−1, when the gene/protein *n* is a repressor of pathway excitation;

1, if the gene/protein *n* is an activator of pathway excitation;

0, when the gene/protein *n* can be both an activator and a repressor of signal transduction;

0.5 and −0.5, respectively, if the gene/protein *n* is more an activator or repressor of the signaling pathway *p*.

The information about the activator/repressor role of a particular gene/protein may be obtained from the analysis of open-access or customized pathway databases and from the literature.

The Boolean flag of *BTIF* (*beyond tolerance interval flag*) equals to zero when the *OYR* value lies within the tolerance limit, and to one when otherwise. During the current study, we have admitted that the *OYR* lies beyond the tolerance limit if it satisfies simultaneously the two criteria. First, it either higher than 3/2 or lower than 2/3, and, second, the expression level for a corresponding gene from an old patient of an individual patient differs by more than two standard deviations from the average expression level for the same gene from a set of analogous young tissue/organ samples.

We propose a new computational approach for identifying and rating the variety of factors including small molecules, peptides, stress factors and conditions with the known effects on the transcriptomes at different ages of one or more cell or tissue types or known targets (Figure [1A](#F1){ref-type="fig"}). The approach may be used for general geroprotector screening, but after the validation of the algorithms *in vivo* and *in vitro* may be expanded to identify and predict the efficacy of personalized aging-suppressive intervention regimens for individual patients based on the transcriptome information from various tissue biopsies and blood samples.

The generic geroprotector rating approach involves collecting the transcriptome data sets from young and old patients and normalizing the data for each cell and tissue type, evaluating the pathway activation strength (PAS) for each individual pathway (Figure [1B](#F1){ref-type="fig"}) and constructing the pathway cloud (PC, Figure [1C](#F1){ref-type="fig"}) and screen for drugs or combinations that minimize the signaling pathway cloud disturbance (SPCD, Figure [1D](#F1){ref-type="fig"}) by acting on one or multiple elements of the pathway cloud. Drugs and combinations may be rated by their ability to compensate the changes in signaling pathway activation patterns that are related to aging, thus bringing all the *PAS* values for the general set of the pathways as close to zero as possible. Since many of the drugs approved for use in humans have known molecular targets and some have been screened for the impact on longevity in model organisms (Ye et al., [@B43]), the predictions may be then tested both *in vitro* and *in vivo* on human cells and on model organisms such as rodents, nematodes and flies to validate the screening and rating algorithms.

Conclusion {#s1}
==========

Longevity studies of aging-suppressive drug efficiency in higher mammals take several years and decades and may cost millions of dollars. An intelligent process for predicting the activity and ranking the geroprotective activity of various factors and strengthening the prediction in rapid and cost-effective studies on cell cultures and model organisms may help increase the longevity dividend of these studies. In this paper we propose a method for *in silico* screening and ranking of drugs and other factors that act on many signaling pathways implicated in aging processes by calculating their ability to minimize the difference between signaling pathway activation patterns in cells of young and old patients and confirming the results using *in vivo* and *in vitro* studies.
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